RE:RE:RE:RE:Feb 24 th release of 4thQuarter RedulsLet's do an experiment. First, try to adjust today's PR to make it blander. Second, try to adjust it to make it enticing to prospective investors. I would submit an effort to make it blander would be much more difficult than using it to build some anticipation - even if the meat we are looking for comes at a different point in time than the earnings call. Wino, you have made excellent proposed PR's in the past for TH. I am sure you could improve the current offering with relative ease. TH is just terribly deficient in shareholder communications and has been for a very long time. I am not sure how fixing this has not become a priority for Paul. He has done a lot of things right but he has not been rewarded by the market for doing so. He should be quite concerned about this as the share price is the ultimate arbiter of whether he is a success or failure. As a reminder of just some of TH's failures on this front: 1.) Losing home town shareholder CDP's confidence. You know you have screwed up royally when you cannot keep them on board. 2.) Having an earnings call where no analysts attended. 3.) Never addressing TH's chronically poor analyst coverage - indeed they have made it far worse! The ONO put the final nail in that coffin. 4.) They ticked me, one of their largest shareholders, off to the point I will not even bother to speak with them. And I am really hard to tick off as my long and peaceable ownership of the stock through a lot of drama suggests. 5.)Despite hiring various IR consultants and a capable IR officer, not much progress was made and actually, TH went backwards with regard to analyst coverage. I could go on but it is evident they have a big problem in this area and that it has cost us all a lot of money. Good phase 1a results will help TH redefine the image of the company but unless there is a big makeover, we will all likely be left knowing a lot of meat was unfortunately left on the bone.
Wino115 wrote: It's pretty standard so I don't think one can infer much of anything except the plain language of what they say --quarterly results and update. In the past, they've usually had separate PRs for something meaningful so we ought to expect that for this trial. Trials don't conform to the earnings calendar or fiscal year of a company and would involve getting interpretive data from the lead PI down at MD Anderson and possibly FDA. You'd want to hear what the lead doctors are thinking and form a real solid plan. Let's not forget PL has mentioned a few times that the 1a data and their lab work could inform the ultimate design of 1b. If they want to move quickly to 1b, as was stated to the investor groups, you'd have to be having those conversations with MD Anderson and FDA now.
I do notice Dubuc is still IR, so that hasn't changed. They are probably down to a short list at least and maybe they'll be announced in a few weeks. Usually depends on hiring exit issues. I'd hope they find a top notch pro with serious insitutional AND retail heft in biotechs who knows how to frame the important issues and discuss them. They've definitely gotten a lot better around that compared to a year ago.
SPCEO1 wrote: I have a question for the board - is there anything in the release today that caused your heart to skip a beat with anticipation? No, I didn't think so. Maybe that is because they are not yet ready to tell us anything important but maybe it is because they just do not know how to, or simply don't want to, build enthuisiam among investors for their prospects. Supposedly Paul is a marketing expert but he has not yet applied those skills to his interactions with investors. If I were a new potential investor in TH, I don't think I would be inspired to be on that call by the tone of that press release.